$42.28
arrow_drop_down3.38%Key Stats | |
---|---|
Open | $43.80 |
Prev. Close | $43.47 |
EPS | -2.75 |
Dividend | Non-Dividend |
Next Earnings Date | - |
Dividend Yield % | - |
PE Ratio | - |
LOW | HIGH | |
---|---|---|
Day Range | 42.78 | 44.13 |
52 Week Range | 22.11 | 53.18 |
Ratios | |
---|---|
EPS | -2.75 |
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Period: Next 12 Months
•Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Analyst Expectations For Celldex Therapeutics's Future - Benzinga
Celldex Therapeutics to Present at Jefferies Healthcare Conference
Analyst Expectations For Celldex Therapeutics's Future
Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024
Wall Street Analysts Think Celldex (CLDX) Could Surge 87.27%: Read This Before Placing a Bet
Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis